Published in Antimicrob Agents Chemother on December 01, 1994
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet (1993) 10.45
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro. Antimicrob Agents Chemother (1986) 1.66
Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem (1990) 1.60
Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (1991) 1.37
Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother (1992) 1.29
A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis (1991) 1.24
Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit (1991) 1.11
Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS (1989) 1.08
In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes. Ther Drug Monit (1990) 1.05
Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monit (1992) 0.90
Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics (2001) 2.79
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet (2001) 1.87
Effect of pharmacist intervention on control of resistant hypertension. Am J Hosp Pharm (1986) 1.17
Mapping of bactericidal epitopes on the P2 porin protein of nontypeable Haemophilus influenzae. Infect Immun (1994) 1.16
Clinical pharmacology quality assurance for HIV and related infectious diseases research. Clin Pharmacol Ther (2013) 1.12
Didanosine. Ann Pharmacother (1992) 1.06
2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis (1990) 0.98
Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1987) 0.95
Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy (1997) 0.93
Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy (1995) 0.90
Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res (1993) 0.86
Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther (1986) 0.86
Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. HIV Med (2011) 0.86
Radioimmunoassay of zidovudine: extended use and potential application. Ther Drug Monit (1997) 0.85
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. J Infect Dis (1995) 0.84
Didanosine measurement by radioimmunoassay. Antimicrob Agents Chemother (1996) 0.83
Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother (2001) 0.83
Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother (1999) 0.83
Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit (1987) 0.82
Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr (2000) 0.82
Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy (1996) 0.82
Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. Pharmacotherapy (1993) 0.80
Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin. J Infect Dis (1986) 0.80
Clinically important interaction of cyclosporine and erythromycin. Transplantation (1987) 0.79
Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother (1993) 0.78
Peritoneal transport of cefonicid. Antimicrob Agents Chemother (1987) 0.78
In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res (1994) 0.78
Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother (1998) 0.78
Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin Infect Dis (1998) 0.78
Zalcitabine. Ann Pharmacother (1993) 0.77
Granulocyte-macrophage colony-stimulating factor and zidovudine in the treatment of neutropenia and human immunodeficiency virus infection. Pharmacotherapy (1992) 0.77
Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. Ann Pharmacother (1992) 0.77
Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother (1994) 0.76
Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother (1998) 0.75
Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des (2006) 0.75
Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc (1993) 0.75
In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res (1996) 0.75
Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection. Pharmacotherapy (1999) 0.75
Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. Transplantation (1989) 0.75
Vancomycin-associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis. Drug Intell Clin Pharm (1988) 0.75
Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy. Hosp Formul (1993) 0.75